Personalized Anesthesia in Hematology

Dorgalaleh, Akbar; Bahraini, Mehran; Ahmadi, Seyed Esmaeil

doi:10.1007/978-3-030-53525-4_11

Cited by 3 publications

(2 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the era of personalized medicine, the development of gene editing tools such as CRISPR/CAS9, and viral and non-viral based gene therapies have shown to be very promising [ 768 ]. As such MYC could be a promising choice for gene manipulation approaches.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

et al. 2021

View full text Add to dashboard Cite

MYC oncogene is a transcription factor with a wide array of functions affecting cellular activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to the multi-functionality of MYC, its expression is regulated at multiple levels. Deregulation of this oncogene can give rise to a variety of cancers. In this review, MYC regulation and the mechanisms by which MYC adjusts cellular functions and its implication in hematologic malignancies are summarized. Further, we also discuss potential inhibitors of MYC that could be beneficial for treating hematologic malignancies.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Personalized cancer therapy based on a repertoire of DNA repair deficiencies in patients with hematology malignancies can achieve tumor selective therapy and low-side effects. Molecular profiling of tumors will also help clinicians to adjust the dose of chemotherapy in combined-modality strategies in order to reduce the toxicity of current treatments for hematologic malignancies [ 245 , 246 ].…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment

et al. 2021

View full text Add to dashboard Cite

Chromosomal translocations are the main etiological factor of hematologic malignancies. These translocations are generally the consequence of aberrant DNA double-strand break (DSB) repair. DSBs arise either exogenously or endogenously in cells and are repaired by major pathways, including non-homologous end-joining (NHEJ), homologous recombination (HR), and other minor pathways such as alternative end-joining (A-EJ). Therefore, defective NHEJ, HR, or A-EJ pathways force hematopoietic cells toward tumorigenesis. As some components of these repair pathways are overactivated in various tumor entities, targeting these pathways in cancer cells can sensitize them, especially resistant clones, to radiation or chemotherapy agents. However, targeted therapy-based studies are currently underway in this area, and furtherly there are some biological pitfalls, clinical issues, and limitations related to these targeted therapies, which need to be considered. This review aimed to investigate the alteration of DNA repair elements of C-NHEJ and A-EJ in hematologic malignancies and evaluate the potential targeted therapies against these pathways.

show abstract

Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy

et al. 2023

View full text Add to dashboard Cite

Personalized Anesthesia in Hematology

Cited by 3 publications

References 146 publications

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment

Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy

Contact Info

Product

Resources

About